Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 51

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 51
---
 accrued liabilities and prepaid expenses.
Accounts payable, accrued and prepaid expenses was primarily composed of research and development payables, consultant costs,
insurance costs, legal and accounting expenses.

For
the six months ended June 30, 2024, operating activities used $3.5 million of cash, primarily due to a net loss of $7.7 million offset
by $0.1 million change in accounts payable, accrued and prepaid expenses. Accounts payable, accrued and prepaid expenses was primarily
composed of research and development payables, consultant costs, insurance costs, legal and accounting expenses.

Net
Cash from Financing Activities

For
the six months ended June 30, 2025, financing activities provided $1.0 million of cash, resulting primarily from proceeds from sale of
common stock.

For
the six months ended June 30, 2024, financing activities provided $5.3 million of cash, resulting primarily from $5.8 million in proceeds
from sale of common stock, less offering costs, offset by $0.5 million payments to related parties, and $0.1 million of repayments under
related party line of credit.

Item
3. Quantitative and Qualitative Disclosures About Market Risk

We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and therefore are not required to provide the information
under this item per Item 305(e) of Regulation S-K.

Item
4. Controls and Procedures

Evaluation
of Disclosure Controls and Procedures

As
of the end of the period covered by this Quarterly Report, our management, with the participation of our Chief Executive Officer (our
principal executive officer) and our Chief Financial Officer (our principal financial officer) (the “Certifying Officers”),
conducted evaluations of our disclosure controls and procedures. As defined under Sections 13a-15(e) and 15d-15(e) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), the term “disclosure controls and procedures” means controls
and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in
the rules and forms of the SEC. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure
that information required to be disclosed by an issuer in the reports that it files or submits